Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06577090 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo
A Phase 2 study of Obesity, sponsored by Skye Bioscience.
- Active
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
- 16
- Study locations
NCT06577090: Active Phase 2 study of Obesity, sponsored by Skye Bioscience.
NCT06577090 is a Phase 2 study of Obesity that is active but no longer recruiting, run by Skye Bioscience. The registered enrollment target is 136 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (83% lower). The trial reports 16 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06577090, a Phase 2 study of Obesity, is active but no longer recruiting, sponsored by Skye Bioscience.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
- 16
- Study locations
Study Summary
This is a proof-of-concept study to assess the safety and efficacy of Nimacimab Injection compared to an active and placebo injection control.
Primary Outcome
Percent of participants who have a reduction in body weight
Conditions Studied
Interventions
- BIOLOGICAL Nimacimab injection
- BIOLOGICAL Nimacimab placebo injection
- COMBINATION_PRODUCT semaglutide injection
- BIOLOGICAL Nimacimab 300 mg injection
Study Locations (16)
Georgia
- ACCEL Research Sites - Atlanta
- Center for Advanced Research & Education - Gainesville
Texas
- Velocity Clinical Research, Dallas - Dallas
- Be Well Clinical Studies - Round Rock
Alabama
- Pinnacle Research Group - Anniston
California
- Diablo Clinical Research, Inc. - Walnut Creek
Connecticut
- Chase Medical Research, LLC - Waterbury
Kentucky
- L-MARC Research Center - Louisville
Nebraska
- Be Well Clinical Studies - Lincoln
Nevada
- Palm Research Center - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2024-08-22 |
| Est. Completion | 2027-02-28 |
| Phase | Phase 2 |
What the registry record for NCT06577090 still lists
NCT06577090 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which Nimacimab injection is the first listed.
NCT06577090 lists 16 locations in 14 states (Georgia, Texas, Alabama).
Frequently Asked Questions
What is clinical trial NCT06577090 about?
NCT06577090 is a clinical study titled "Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo". This is a proof-of-concept study to assess the safety and efficacy of Nimacimab Injection compared to an active and placebo injection control.
What is the current status of trial NCT06577090?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2024-08-22. Estimated completion is 2027-02-28.
What conditions does trial NCT06577090 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT06577090?
The interventions under investigation include: Nimacimab injection (BIOLOGICAL), Nimacimab placebo injection (BIOLOGICAL), semaglutide injection (COMBINATION_PRODUCT), Nimacimab 300 mg injection (BIOLOGICAL).
Who is sponsoring clinical trial NCT06577090?
This trial is sponsored by Skye Bioscience, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06577090 being conducted?
This trial has 16 study locations across Alabama, California, Connecticut, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06577090's enrollment target sits among peer trials
136 407th of 1053 higher than 641 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI